adesso (ADN1) Q1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 TU earnings summary
3 Feb, 2026Executive summary
Achieved 11% organic sales growth to EUR 353.4 million in Q1 2025, outperforming peers in a challenging macroeconomic environment.
Maintained a headcount of over 10,400, with a 5–6% year-over-year increase and low attrition rate (~8%), supporting operational scalability.
Operating result and EBITDA remained stable at EUR 17.8 million, with margin subdued by higher personnel and material costs.
Focused on IT services (90% of sales) and industry-specific solutions, with a diversified portfolio across insurance, banking, health, public, automotive, manufacturing, retail, and utilities.
Consolidated earnings for Q1 2025 were negative at EUR -4.1 million, down 23% year-over-year, mainly due to increased depreciation and financial expenses.
Financial highlights
Revenue grew 11% year-over-year to EUR 353.4 million, with 84% generated in Germany, which saw 13% growth.
EBITDA margin declined to 5.1% from 5.6% year-over-year, as EBITDA grew only 1% year-over-year.
Earnings per share were EUR -0.54, down from EUR -0.49 in Q1 2024.
Personnel costs rose 9% due to increased staff and normal salary increases.
Free cash flow and operating cash flow were negative in Q1 2025, reflecting higher investments, lease repayments, and contract assets.
Outlook and guidance
Guidance for 2025 confirmed: revenue EUR 1.35–1.45 billion, EBITDA EUR 105–125 million.
Margin improvement and majority of earnings expected in H2 2025, driven by higher utilization, more working days, and sector recovery.
EBITDA margin target of 8%+ remains on track, with profitability measures expected to yield a slightly improved margin over the year.
Latest events from adesso
- Sales up 16% to €631.1m, but negative EPS and lower EBITDA guidance due to margin pressure.ADN1
H1 20241 Feb 2026 - Record sales and profitability in Q3 2024, with strong outlook and share buyback underway.ADN1
Q3 2024 TU14 Jan 2026 - Sales, EBITDA, and EPS surged, with robust sector growth and guidance at the upper end.ADN1
Q3 202515 Nov 2025 - 12% sales and 34% EBITDA growth in H1 2025, but free cash flow and equity ratio declined.ADN1
Q2 202518 Aug 2025 - 14% organic growth and margin gains set stage for further expansion in 2025.ADN1
H2 20245 Jun 2025